Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

NCT01946477 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Pomalidomide
DRUG: Dexamethasone
DRUG: Daratumumab

Sponsor

Celgene